December 2022

Physician involvement can determine how much patients benefit from services provided.

Encourage professional development, foster resiliency, and engage nurse leaders to create an environment that not only brings in new nurses, but keeps them.

CAR T-cell therapy represents a viable treatment option for many patients, but there are potentially serious adverse events.

Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.

As the treatment paradigm continues to evolve, nurses play a key role in educating patients, monitoring treatments, and watching for adverse effects.

The new model of care will seek to increase value-based care for patients receiving chemotherapy.

Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.

The combination of durvalumab and tremelimumab has been approved for patients with unresectable hepatocellular carcinoma. The combination comes with warnings for immune-related adverse events and infusion reactions.

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.

The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.